Merck wins FDA OK for new CMV drug Prevymis, triggering a $122M payday for AiCuris
Five years after bagging the CMV drug letermovir in a $500 million-plus deal with AiCuris, Merck says the FDA has come through with an approval.
While not a blockbuster by most accounts, the drug — to be marketed as Prevymis — demonstrated a significantly reduced the rate of cytomegalovirus infection among patients getting a bone marrow stem cell transplant, comparing the rates in a placebo arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
